Cargando…

Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most prevalent causes of cancer-related death worldwide. Recently, there are many important medical advancements on NSCLC, such as therapies based on tyrosine kinase inhibitors and immune checkpoint inhibitors. Most of these therapies requ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jialiang, Hui, Yan, Zhang, Yanxiang, Zhang, Minghui, Ji, Binbin, Tian, Geng, Guo, Yangqiang, Tang, Min, Li, Lianxing, Guo, Bella, Ma, Tonghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375502/ https://www.ncbi.nlm.nih.gov/pubmed/34422670 http://dx.doi.org/10.3389/fonc.2021.725938

Ejemplares similares

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer
por: Peng, Muyun, et al.
Publicado: (2020)

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Yuan, Shuai, et al.
Publicado: (2020)

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer
por: Hong, Yang, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

The Role of Circulating Biomarkers in Lung Cancer
por: Herath, Sayuri, et al.
Publicado: (2022)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis
por: Wan, Lingling, et al.
Publicado: (2021)

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
por: Knapp, Brendan, et al.
Publicado: (2022)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
por: Fang, Xiaoxu, et al.
Publicado: (2022)

Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients
por: Raczkowska, Justyna, et al.
Publicado: (2023)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low‐Dose Computed Tomography
por: Kan, Chin Fung Kelvin, et al.
Publicado: (2021)

Tumor-Derived Exosomal miRNAs as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
por: Zhang, Zhijun, et al.
Publicado: (2020)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Weighted-Support Vector Machine Learning Classifier of Circulating Cytokine Biomarkers to Predict Radiation-Induced Lung Fibrosis in Non-Small-Cell Lung Cancer Patients
por: Yu, Hao, et al.
Publicado: (2021)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma
por: Guan, Shasha, et al.
Publicado: (2022)

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
por: Hanssen, Annkathrin, et al.
Publicado: (2015)

Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients
por: Zhang, Jiexia, et al.
Publicado: (2022)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
por: van Rees, Jan M., et al.
Publicado: (2023)

Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer
por: Zhang, Jinghua, et al.
Publicado: (2021)

Targeted Therapies and Biomarkers in Small Cell Lung Cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2020)

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer
por: Zhang, Ji, et al.
Publicado: (2018)

Plasma exosomal tRNA‐derived fragments as diagnostic biomarkers in non-small cell lung cancer
por: Zheng, Baibing, et al.
Publicado: (2022)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma
por: Zhou, Wen-Da, et al.
Publicado: (2022)

Identifying Genomic Alterations in Small Cell Lung Cancer Using the Liquid Biopsy of Bronchial Washing Fluid
por: Zhai, Jinfang, et al.
Publicado: (2021)

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer
por: Gargiuli, Chiara, et al.
Publicado: (2022)

Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison
por: Chen, Yi-Lin, et al.
Publicado: (2019)

Precision Oncology: Artificial Intelligence and DNA Methylation Analysis of Circulating Cell-Free DNA for Lung Cancer Detection
por: Bahado-Singh, Ray, et al.
Publicado: (2022)

Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer
por: Zhang, Jie, et al.
Publicado: (2023)

WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer
por: Li, Zheng, et al.
Publicado: (2022)

A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma
por: Shen, Nan, et al.
Publicado: (2019)

Current treatments for non-small cell lung cancer
por: Guo, Qianqian, et al.
Publicado: (2022)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer
por: Cai, Jun, et al.
Publicado: (2022)

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer
por: Liang, Nan, et al.
Publicado: (2023)

Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation
por: Deng, Lei, et al.
Publicado: (2021)

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
por: Faugeroux, Vincent, et al.
Publicado: (2014)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
por: Brega, Elisa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2veepqqldk0pnt7fvkv2e12qkm